Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche Shakes Up R&D, Closes Nutley Operations

This article was originally published in The Pink Sheet Daily

Executive Summary

Roche will shut down its Nutley, N.J., pharma operations – once its U.S. headquarters – by the end of 2013 in a cost-saving measure that will leave only a small group of employees on the East Coast.

You may also be interested in...

Roche Reviews Its Research Priorities With Opening Of Translational Research Center

Oncology may consume a disproportionate percentage of Roche’s R&D budget and generate the bulk of its revenues, but at a day-long symposium celebrating the opening of Roche’s new translational research center in NYC, the company’s scientific leaders highlighted its priorities in other complex diseases.

Roche Opens NY R&D Hub As Its pRED Head Vows To Boost Alliances

Amid a day of celebrations around the long-awaited opening of its translational and clinical research center in New York, Roche’s new head of research and early development, the superstar scientist John Reed, offered a glimpse of how the organization is restructuring its external relationships and its priorities going forward.

Roche CEO Severin Schwan: Fueled By Innovation, Emerging Markets

Roche’s CEO Severin Schwan says the Swiss group’s recent revamps, lack of patent expiries, and ongoing drug innovations give the world’s largest maker of cancer drugs a strong position to expand its sales globally, helped by new cutting-edge therapies and creative business approaches.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts